Sec Form 13G Filing - Quested Robert filing for Silence Therapeutics plc (SLN) - 2021-02-17

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )   *

 

 

Silence Therapeutics plc

(Name of Issuer)

 

Ordinary Shares, par value £0.05 per share

(Title of Class of Securities)

 

G8128Y157

(Cusip Number)

 

December 31, 2020

(Date of Event which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

       Rule 13d-1(b)

       Rule 13d-1(c)

       Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following pages)

 

 


Page 1 of 5 Pages 


 

 

 

13G

CUSIP No. G8128Y157

 

1

NAMES OF REPORTING PERSONS

 

Robert Quested

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            

(a) 

(b) 

 

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Gibraltar

NUMBER OF

 

SHARES BENEFICIALLY

OWNED BY

 

EACH

 

REPORTING PERSON WITH

5

SOLE VOTING POWER

 

7,620,279

6

SHARED VOTING POWER

 

0

7

SOLE DISPOSITIVE POWER

 

7,620,279

8

SHARED DISPOSITIVE POWER

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

7,620,279

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

CERTAIN SHARES (See Instructions)

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.5%

12

TYPE OF REPORTING PERSON ( See Instructions)

 

IN

 

 

 

 

 


Page 2 of 5 Pages


 

Item 1.   Issuer

 

(a)         Name of Issuer:

 

Silence Therapeutics plc (the “Company”)

 

(b)         Address of Issuer’s Principal Executive Offices:

 

72 Hammersmith Road

London W14 8TH

United Kingdom

 

Item 2.   Identity and Background

 

Title of Class of Securities and CUSIP Number (Items 2(d) and (e))

 

This statement relates to ordinary shares, par value £0.05 per share (the “Shares”), of the Company. The CUSIP number of the Shares is G8128Y157.

 

Name of Persons Filing, Address of Principal Business Office and Citizenship (Items 2(a), (b) and (c))

 

This statement is filed by Robert Quested (the “Reporting Person”).

 

The address of the Reporting Person is 65 The Anchorage, Rosia Road, Gibraltar GX11 1AD.

 

 

 

Item 3.   If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is an Entity Specified in (a) - (k):

 

Not applicable.

 

Item 4.   Ownership

 

The percentages used herein and in the rest of this Schedule 13G are calculated based upon 89,381,913 Shares issued and outstanding as of February 4, 2021, as disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on February 8, 2021.

 

 

(a)

Amount beneficially owned: 7,620,279 Shares

 

 

(b)

Percent of class: 8.5%

 

 

(c)

(i) Sole power to vote or direct the vote: 7,620,279

(ii) Shared power to vote or direct the vote: 0

(iii) Sole power to dispose or direct the disposition: 7,620,279

(iv) Shared power to dispose or direct the disposition of: 0

 

Item 5.   Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be a beneficia l owner of more than five percent of the class of securities, check the following:

 

Item 6.   Ownership of More than Five Percent on Behalf of Another Person

 

Not applicable.

 

Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

 

Not applicable.

 

Item 8.   Identification and Classification of Members of the Group

 

Not applicable.

Page 3 of 5 Pages


 

 

 

 

 

Item 9.   Notice of Dissolution of Group

 

Not applicable.

 

Item 10.  Certification

 

Not applicable.

 

 

 

 

Page 4 of 5 Pages


 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: February 17, 2021

 

Robert Quested

 

 

By:

/s/ Robert Quested

 

 

 

 

 

Name: Robert Quested

 

 

 

 

 

 

Page 5 of 5 Pages